Weight gain associated with the -759 C/T polymorphism of the 5HT2C receptor and olanzapine

American Journal of Medical Genetics - Neuropsychiatric Genetics

Volumn 134 B, Issue 1, 2005, Pages 76-78

  Ellingrod, Vicki L ^a,c   Perry, Paul J ^a,b   Ringold, John C ^b   Lund, Brian C ^a   Bever Stille, Kristy ^a   Fleming, Frank ^b   Holman, Timothy L ^a,b   Miller, Del ^b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c BCPP   (United States)

Author keywords

Antipsychotics; Olanzapine; Polymorphisms; Schizophrenia; Serotonin; Weight gain

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; DNA; OLANZAPINE; RISPERIDONE; SEROTONIN 2C RECEPTOR;

ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; DRUG INDUCED DISEASE; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MALE; MENTAL DISEASE; OBESITY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; RATING SCALE; RECEPTOR GENE; SCALE FOR ASSESSMENT OF NEGATIVE SYMPTOMS; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT OUTCOME; WEIGHT GAIN;

ALLELES; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BODY WEIGHT; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, SEROTONIN, 5-HT2C; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 15744364142     PISSN: 15524841     EISSN: 1552485X     Source Type: Journal    
DOI: 10.1002/ajmg.b.20169     Document Type: Article

References (15)

1. Allison DB, Mentore JL, Moonseon H, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ. 1999a. Antipsychotic-induced weight gain: A comprehensive research synthesis. Am J Psychiatry 156:1686-1696.
2. Andreasen N. 1983. Scale for the assessment of negative symptoms (SANS). Iowa City, Iowa: The University of Iowa.
3. Basile VS, Masellis M, DeLuca V, Meltzer HY, Kennedy JL. 2002. -759C/T genetic variation of the 5HT2C receptor and clozapine-induced weight. Lancet 360:1790-1791.
4. Basson BR, Kinon BJ, Taylor CC, Syzymanksi KA, Gilmore JA, Tollefson GD. 2001. Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol or risperidone. J Clin Psychiatry 62:231-238.
5. Lappalainen J, Zhang L, Den M, Oz M, Ozaki N, Yu D-H, Virkkunen M, et al. 1995. Identification, expression, and pharmacology of a Cys23-Ser23 substitution in the human 5-HT2C receptor gene (HTR2C). Genomics 27:274-279.
6. Overall J, Gorham D. 1962. Brief psychiatric rating scale. Psychol Rep 10: 799-812.
7. Perry PJ, Sanger T, Beasley C. 1997. Olanzapine plasma concentrations and clinical response in acutely ill schizophrenic patients. J Clin Psychopharmacol 17:472-476.
8. Reynolds GP, Zhang AJ, Zhang XB. 2002. Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism. Lancet 359:2086-2087.
9. Reynolds GP, Zhang Z, Zhang X. 2003. Polymorphism of the promoter region of the serotonin 5-HT2C receptor gene and clozapine-induced weight gain. Am J Psychiatry 160:677-679.
10. Shih JC, Zhu Q, Chen K. 1996. Determination of transcription initiation sites and promoter activity of the human 5-HT2A receptor gene. Behav Brain Res 73:59-62.
11. Stahl SM. 1998. Neuropharmacology of obesity: My receptors made me eat it. J Clin Psychiatry 59:447-448.
12. Tecott LH, Sun LM, Akana SF, Strack AM, Lowenstein DH, Dallman MF, Julis D. 1995. Eating disorder and epilepsy in mice lacking 5-HT2C serotonin receptors. Nature 374:542-546.
13. Tsai S-J, Hong C-J, Yu YW-Y, Lin C-H. 2002. -759C/T genetic variation of the 5HT2C receptor and clozapine-induced weight. Lancet 360:1790.
14. Umbricht D, Kane JM. 1996. Medical complications of new antipsychotic drugs. Schizophr Bull 22:475-483.
15. Yuan X, Yamada K, Ishiyama-Shigemoto S, Koyama W, Nonaka K. 2000. Identification of polymorphic loci in the promoter region of the serotonin 5-HT2C receptor gene and their association with obesity and Type II diabetes. Diabetologia 43:373-376.